Novo Nordisk stock falls after cardiovascular trial failure
Novo Nordisk shares slid after the company said ziltivekimab, its interleukin-6 inhibitor, did not reduce major adverse cardiovascular events in the Phase 3 ZEUS trial, posting a hazard ratio of 0.99 versus placebo across more than 6,300 patients. The setback eliminates a potential revenue source beyond its GLP-1 franchise. A U.S. judge also ruled that a shareholder securities fraud lawsuit related to CagriSema can proceed, alleging an undisclosed mid-trial protocol change. Combined with growing competition from Eli Lilly, these developments create immediate investor concern and remove near-term pipeline upside.
Phase 3 cardiovascular trial showed no benefit and removed a pipeline catalyst
Context
The company reported ZEUS Phase 3 results showing no benefit. A judge allowed a CagriSema securities suit to proceed. Market focus may shift to legal outcomes and competitor approvals next.
The full analysis
19 dimensions on this story — world impact, market read, and what happens next.
- Full ContextLocked
- Affected SectorsLocked
- Stock ImpactLocked
- Economic IndicatorLocked
- Investor RelevanceLocked
- Professional RelevanceLocked
- Watch PointsLocked
- Probability of ChangeLocked
- Debate PointsLocked
- Prerequisite KnowledgeLocked
- Follow-up QuestionsLocked